tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Whalen HR et al. | High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. | 2017 | Transplantation | pmid:26950724 |
| de Fijter JW et al. | Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. | 2017 | Am. J. Transplant. | pmid:28027625 |
| Zidan AS | Taste-masked tacrolimus-phospholipid nanodispersions: dissolution enhancement, taste masking and reduced gastric complications. | 2017 | Pharm Dev Technol | pmid:26811031 |
| Ueno P et al. | Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. | 2017 | Transplantation | pmid:27490418 |
| Jouve T et al. | New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients. | 2017 | Expert Opin Drug Saf | pmid:28494654 |
| Sanghavi K et al. | Genotype-guided tacrolimus dosing in African-American kidney transplant recipients. | 2017 | Pharmacogenomics J. | pmid:26667830 |
| Heemann U and Viklicky O | Is trough level variability the new tool for identifying patients at risk for rejection after transplantation? | 2017 | Nephrol. Dial. Transplant. | pmid:28186537 |
| Størset E et al. | Response to: 'Response to: Bodyweight-adjustments introduce significant correlations between CYP3A metrics and tacrolimus clearance'. | 2017 | Br J Clin Pharmacol | pmid:28374426 |
| Lawrance IC et al. | Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis. | 2017 | Clin. Gastroenterol. Hepatol. | pmid:28286194 |
| Morita M et al. | The onset risk of carcinoma in patients continuing tacrolimus topical treatment for oral lichen planus: a case report. | 2017 | Odontology | pmid:27368962 |
| Shimizu S et al. | Reduction of FR900525 using an S-(2-aminoethyl) l-cysteine-resistant mutant. | 2017 | J. Biosci. Bioeng. | pmid:28185832 |
| Hamada T et al. | Phenotypic analysis of circulating T-cell subset and its association with burden of skin disease in patients with chronic actinic dermatitis: a hematologic and clinicopathologic study of 20 subjects. | 2017 | Int. J. Dermatol. | pmid:28176301 |
| Chung BH et al. | Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. | 2017 | Transplantation | pmid:28107277 |
| Ak K et al. | Tacrolimus-Eluting Suture Inhibits Neointimal Hyperplasia: An Experimental In Vivo Study in Rats. | 2017 | Eur J Vasc Endovasc Surg | pmid:28065442 |
| Ivulich S et al. | Clinical Challenges of Tacrolimus for Maintenance Immunosuppression Post-Lung Transplantation. | 2017 | Transplant. Proc. | pmid:29149976 |
| Obaidat RM et al. | Using Supercritical Fluid Technology (SFT) in Preparation of Tacrolimus Solid Dispersions. | 2017 | AAPS PharmSciTech | pmid:27116202 |
| Khan SA et al. | Improvement in baroreflex control of renal sympathetic nerve activity in obese Sprague Dawley rats following immunosuppression. | 2017 | Acta Physiol (Oxf) | pmid:28456134 |
| Wan T et al. | Dual roles of TPGS based microemulsion for tacrolimus: Enhancing the percutaneous delivery and anti-psoriatic efficacy. | 2017 | Int J Pharm | pmid:28629978 |
| Tremblay S and Alloway RR | Clinical Evaluation of Modified Release and Immediate Release Tacrolimus Formulations. | 2017 | AAPS J | pmid:28717926 |
| Burbulla LF et al. | Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. | 2017 | Science | pmid:28882997 |